Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK556370PMID: 32352698
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 72599-27-0
Drug Levels and Effects
Summary of Use during Lactation
No published experience exists with miglustat during breastfeeding. Because of the lack of information and its side effect profile, most sources consider breastfeeding to be contraindicated during maternal miglustat therapy.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Miglustat
CAS Registry Number
72599-27-0
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.[J Inherit Metab Dis. 2004]Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, et al. J Inherit Metab Dis. 2004; 27(6):757-66.
- Review [Recent research advances of 1-deoxynojirimycin and its derivatives].[Zhongguo Zhong Yao Za Zhi. 2018]Review [Recent research advances of 1-deoxynojirimycin and its derivatives].Tong TT, Zhao EH, Gao HL, Xu YH, Zhao YJ, Fu G, Cui HJ. Zhongguo Zhong Yao Za Zhi. 2018 May; 43(10):1990-1997.
- Unexpected cure from cutaneous leukocytoclastic vasculitis in a patient treated with N-butyldeoxynojirimycin (miglustat) for Gaucher disease.[Adv Med Sci. 2012]Unexpected cure from cutaneous leukocytoclastic vasculitis in a patient treated with N-butyldeoxynojirimycin (miglustat) for Gaucher disease.Machaczka M, Klimkowska M, Hägglund H. Adv Med Sci. 2012 Jun 1; 57(1):169-73.
- Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.[Pharmacoepidemiol Drug Saf. 2015]Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.Brand M, Muller A, Alsop J, van Schaik IN, Bembi B, Hughes D. Pharmacoepidemiol Drug Saf. 2015 Mar; 24(3):329-33. Epub 2015 Feb 5.
- Review The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.[J Inherit Metab Dis. 2003]Review The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, et al. J Inherit Metab Dis. 2003; 26(6):513-26.
- Miglustat - Drugs and Lactation Database (LactMed®)Miglustat - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...